Autopsy report · NCT03399578

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

“The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 6 months before it stopped.
• 29 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

University of Oxford

Sponsor type

University, hospital or other

Conditions

MERS (Middle East Respiratory Syndrome)

Interventions

ChAdOx1 MERS

Participants

29

Sites

1

Countries

United Kingdom

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.